Human Versican ELISA Kit (ab283883)
Key features and details
- One-wash 90 minute protocol
- Sensitivity: 68.5 pg/ml
- Range: 141 pg/ml - 9000 pg/ml
- Sample type: Cell culture media, Cit plasma, EDTA Plasma, Hep Plasma, Serum
- Detection method: Colorimetric
- Assay type: Sandwich (quantitative)
- Reacts with: Human
Overview
-
Product name
Human Versican ELISA Kit
See all Versican kits -
Detection method
Colorimetric -
Precision
Intra-assay Sample n Mean SD CV% Plasma 8 4.1% Inter-assay Sample n Mean SD CV% Plasma 4 6.9% -
Sample type
Serum, Cell culture media, Hep Plasma, EDTA Plasma, Cit plasma -
Assay type
Sandwich (quantitative) -
Sensitivity
68.5 pg/ml -
Range
141 pg/ml - 9000 pg/ml -
Recovery
Sample specific recovery Sample type Average % Range Serum 104 100% - 109% Cell culture media 85 83% - 87% Hep Plasma 97 85% - 104% EDTA Plasma 110 109% - 112% Cit plasma 99 86% - 106% -
Assay time
1h 30m -
Assay duration
One step assay -
Species reactivity
Reacts with: Human -
Product overview
Human Versican ELISA Kit (ab283883) is a single-wash 90 min sandwich ELISA designed for the quantitative measurement of Versican protein in serum, plasma, and cell culture supernatant. It uses our proprietary SimpleStep ELISA® technology. Quantitate Human Versican with 68.5 pg/ml sensitivity.
SimpleStep ELISA® technology employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our SimpleStep ELISA® plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. See the SimpleStep ELISA® protocol summary in the image section for further details. Our SimpleStep ELISA® technology provides several benefits:
- Single-wash protocol reduces assay time to 90 minutes or less
- High sensitivity, specificity and reproducibility from superior antibodies
- Fully validated in biological samples
- 96-wells plate breakable into 12 x 8 wells strips
A 384-well SimpleStep ELISA® microplate (ab203359) is available to use as an alternative to the 96-well microplate provided with SimpleStep ELISA® kits.
-
Notes
Versican, also known as Versican Core Protein, is a proteoglycan in the extracellular matrix that binds with hyaluronic acid. Versican plays a role in cell adhesion, migration, and proliferation, as well as signaling in the extracellular matrix.
-
Platform
Pre-coated microplate (12 x 8 well strips)
Properties
-
Storage instructions
Store at +4°C. Please refer to protocols. -
Components 1 x 96 tests 10X Human Versican Capture Antibody 1 x 600µl 10X Human Versican Detector Antibody 1 x 600µl 10X Wash Buffer PT (ab206977) 1 x 20ml Antibody Diluent CPI - HAMA Blocker (ab193969) 1 x 6ml Human Versican Lyophilized Recombinant Protein 2 vials Plate Seals 1 unit Sample Diluent NS (ab193972) 1 x 50ml SimpleStep Pre-Coated 96-Well Microplate (ab206978) 1 unit Stop Solution 1 x 12ml TMB Development Solution 1 x 12ml -
Research areas
-
Function
May play a role in intercellular signaling and in connecting cells with the extracellular matrix. May take part in the regulation of cell motility, growth and differentiation. Binds hyaluronic acid. -
Tissue specificity
Cerebral white matter and plasma. Isoform V0 and isoform V1 are expressed in normal brain, gliomas, medulloblastomas, schwannomas, neurofibromas, and meningiomas. Isoform V2 is restricted to normal brain and gliomas. Isoform V3 is found in all these tissues except medulloblastomas. -
Involvement in disease
Defects in VCAN are the cause of Wagner syndrome type 1 (WGN1) [MIM:143200]. WGN is a dominantly inherited vitreoretinopathy characterized by an optically empty vitreous cavity with fibrillary condensations and a preretinal avascular membrane. Other optical features include progressive chorioretinal atrophy, perivascular sheating, subcapsular cataract and myopia. Systemic manifestations are absent in WGN. -
Sequence similarities
Belongs to the aggrecan/versican proteoglycan family.
Contains 1 C-type lectin domain.
Contains 2 EGF-like domains.
Contains 1 Ig-like V-type (immunoglobulin-like) domain.
Contains 2 Link domains.
Contains 1 Sushi (CCP/SCR) domain. -
Developmental stage
Disappears after the cartilage development. -
Post-translational
modificationsPhosphorylation sites are present in the extracelllular medium. -
Cellular localization
Secreted > extracellular space > extracellular matrix. - Information by UniProt
-
Alternative names
- Chondroitin sulfate proteoglycan 2
- Chondroitin sulfate proteoglycan core protein 2
- Chondroitin sulfate proteoglycan core protein, cartilage
see all -
Database links
- Entrez Gene: 1462 Human
- Omim: 118661 Human
- SwissProt: P13611 Human
- Unigene: 643801 Human
- Unigene: 715773 Human
Images
-
SimpleStep ELISA technology allows the formation of the antibody-antigen complex in one single step, reducing assay time to 90 minutes. Add samples or standards and antibody mix to wells all at once, incubate, wash, and add your final substrate. See protocol for a detailed step-by-step guide.
-
The Versican standard curve was prepared as described in Section 10. Raw data values are shown in the table. Background-subtracted data values (mean +/- SD) are graphed.
-
The concentrations of Versican were measured in duplicates, interpolated from the target standard curves and corrected for sample dilution. Undiluted samples are as follows: serum 15%, plasma (EDTA) 15%, plasma (citrate) 15%, plasma (heparin) 15%. The interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean target concentration was determined to be 42.2 ng/mL in neat serum, 44.9 ng/mL in neat plasma (EDTA) 39.9 ng/mL in neat plasma (citrate), and 45.5 ng/mL in neat plasma (heparin).
-
Interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean Versican concentration was determined to be 48.9 ng/mL with a range of 28.9 – 60.2 ng/mL.
-
To learn more about the advantages of recombinant antibodies see here.
Datasheets and documents
-
SDS download
-
Datasheet download
References (0)
ab283883 has not yet been referenced specifically in any publications.